More than a decade of Drugs to Watch
Our picks, from 2013 to the present.
In identifying our 2025 Drugs to Watch, we drew on the expertise of more than 160 Clarivate analysts and 11 integrated data sets spanning hundreds of drugs, diseases and markets and covering the whole of the innovation lifecycle.
Drug Name | Company | Therapy Area | Year |
Lovotibeglogene autotemcel | Bluebird Bio Inc. | Beta-thalassemia, Sickle cell disease | 2024 |
Exagamglogene autotemcel | CRISPR Therapeutics, Vertex Pharmaceuticals Inc. | Beta-thalassemia, Sickle cell disease | 2024 |
Ensifentrine | Verona Pharma | COPD | 2024 |
Efanesoctocog alfa | Sanofi SA, Swedish Orphan Biovitrum AB | Hemophilia A | 2024 |
Datopotamab deruxtecan | AstraZeneca plc, Daiichi Sankyo Co. Ltd., NSCLC | Breast cancer, NSCLC | 2024 |
Budesonide | Calliditas Therapeutics AB | Primary immunoglobulin A (IgA) nephropathy/Berger's disease | 2024 |
Niraparib + abiraterone acetate | Johnson & Johnson | Prostate cancer | 2024 |
RSVpreF3 | GlaxoSmithKline plc | Respiratory syncytial virus (RSV) | 2024 |
Aflibercept | Bayer AG, Regeneron Pharmaceuticals Inc. | Diabetic macular edema, Diabetic retinopathy, Wet age-related macular degeneration | 2024 |
RSVpreF | Pfizer Inc. | Respiratory syncytial virus (RSV) | 2024 |
Talquetamab | Johnson & Johnson | Multiple myeloma | 2024 |
Lecanemab | Biogen Inc., Esai Co Ltd. | Alzheimer’s disease | 2022, 2023 |
Foscarbidopa/foslevodopa | AbbVie Inc. | Parkinson’s disease | 2023 |
Deucravacitinib | Bristol-Myers Squibb Co. | Plaque psoriasis | 2023 |
Daprodustat | GlaxoSmithKline plc | Chronic kidney disease (CKD)–related anemia | 2023 |
Capivasertib | AstraZeneca plc | Breast cancer | 2023 |
Donanemab | Eli Lilly and Co. | Alzheimer’s disease | 2022, 2023 |
Bimekizumab | UCB | Plaque psoriasis | 2021, 2023 |
Idelalisib (Zydelig) | Gilead Sciences Inc. | Oncology | 2014 |
Sofosbuvir (Sovaldi) | Gilead Sciences Inc. | Infectious disease | 2014 |
Vilanterol plus umeclidinium (Anoro Ellipta) | GlaxoSmithKline plc, Theravance Biopharma Inc. | Respiratory disease | 2014 |
Filgotinib (GLPG-0634) | Galapagos NV, Gilead Sciences Inc. | Excessive immune response/autoimmunity | 2020 |
Inclisiran (ALN-PCSsc; ALN-60212; PCSK9si; Leqvio) | The Medicines Co. | Cardiovascular disease | 2020 |
Lisocabtagene maraleucel (JCAR-017; Liso-cel) | Celgene Corporation | Oncology | 2020 |
Ofatumumab (OMB-157; Kesimpta) | Novartis International AG | Neurology/psychiatric | 2020 |
Ozanimod (RPC-1063; Zeposia) | Celgene Corporation | Neurology/psychiatric | 2020 |
Rimegepant (BHV-3000; Nurtec) | Biohaven Pharmaceutical Holding Co. Ltd. | Neurology/psychiatric | 2020 |
Sacituzumab govitecan (IMMU-132) | Immunomedics Inc., Medicine Inc. | Oncology | 2020 |
Semaglutide (Rybelsus) | Novo Nordisk A/S | Endocrinology/metabolic disease | 2020 |
Emtricitabine plus tenofovir alafenamide (Descovy) | Gilead Sciences Inc., Japan Tobacco | Infectious disease | 2016 |
Grazoprevir plus elbasvir (MK-5172A) | Merck & Co. | Infectious disease | 2016 |
Obeticholic acid (Ocaliva) | Intercept Pharmaceuticals, Sumitomo Dainippon Pharma | Hepatology | 2016 |
Selexipag (Uptravi) | Actelion, Nippon Shinyaku Co. | Cardiovascular disease | 2016 |
Tenofovir alafenamide plus emtricitabine plus rilpivirine (Odefsey) | Gilead Sciences Inc., Janssen R&D | Infectious disease | 2016 |
Venetoclax (Venclexta; Venclyxto) | AbbVie Inc. | Oncology | 2016 |
Pimavanserin (Nuplazid) | ACADIA Pharmaceuticals | Neurology/psychiatric | 2016 |
Fluticasone furoate plus vilanterol trifenatate (Relovair) | GlaxoSmithKline plc, Theravance Biopharma Inc. | Respiratory disease | 2013 |
Icosapent ethyl ester (Vascepa) | Amarin Corporation plc | Cardiovascular disease | 2013 |
Pomalidomide (Pomalyst) | Celgene Corporation | Oncology | 2013 |
Trastuzumab emtansine (T-DM1) | Roche | Oncology | 2013 |
Umeclidinium plus vilanterol (Zephyr) | GlaxoSmithKline plc, Theravance Biopharma Inc. | Respiratory disease | 2013 |
Apremilast (Otezla) | Celgene Corporation | Excessive immune response/autoimmunity | 2013 |
Apalutamide (Erleada) | Johnson & Johnson | Oncology | 2018 |
Buprenorphine (Sublocade) | Indivior plc | Addiction | 2018 |
Cannabidiol (Epidiolex) | GW Pharmaceuticals plc | Neurology/psychiatric | 2018 |
Elagolix (Orilissa) | AbbVie Inc. | Reproductive health | 2018 |
Emicizumab (Hemlibra) | Chugai, Roche | Hematology | 2018 |
Erenumab (Aimovig) | Amgen, Novartis International AG | Neurology/psychiatric | 2018 |
Lanadelumab (Takhzyro) | Shire | Genetic disorder | 2018 |